Search Results - "Miriam Kull"

Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma by Ng, Yuen Lam Dora, Ramberger, Evelyn, Bohl, Stephan R., Dolnik, Anna, Steinebach, Christian, Conrad, Theresia, Müller, Sina, Popp, Oliver, Kull, Miriam, Haji, Mohamed, Gütschow, Michael, Döhner, Hartmut, Walther, Wolfgang, Keller, Ulrich, Bullinger, Lars, Mertins, Philipp, Krönke, Jan

“…The immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide are highly effective treatments for multiple myeloma. However, virtually all patients…”
Get full text

Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany by Engelhardt, Monika, Shoumariyeh, Khalid, Rösner, Amelie, Ihorst, Gabriele, Biavasco, Francesca, Meckel, Katharina, von Metzler, Ivana, Treurich, Sebastian, Hebart, Holger, Grube, Matthias, Kull, Miriam, Bassermann, Florian, Schäfer-Eckart, Kerstin, Hoferer, Anette, Einsele, Hermann, Rasche, Leo, Wäsch, Ralph

Get full text

Grundlagen der Hämostase by Kull, Miriam Dr

Get full text

The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma by Weißbach, Susann, Langer, Christian, Puppe, Bernhard, Nedeva, Theodora, Bach, Elisa, Kull, Miriam, Bargou, Ralf, Einsele, Hermann, Rosenwald, Andreas, Knop, Stefan, Leich, Ellen

“…Summary Multiple myeloma (MM) is a plasma cell neoplasm that presents with a major biological and clinical heterogeneity. We here investigated the spectrum of…”
Get full text

CDK6 protein expression is associated with disease progression and treatment resistance in multiple myeloma by Steinhart, Johannes, Möller, Peter, Kull, Miriam, Krönke, Jan, Barth, Thomas F. E.

“…Multiple myeloma (MM) is a heterogeneous malignancy of plasma cells. Despite improvement in the prognosis of MM patients after the introduction of many new…”
Get full text

P829: GENOMIC PROFILING IN CFDNA COMPLEMENTS MOLECULAR DIAGNOSIS IN PATIENTS WITH MULTIPLE MYELOMA by Schilhabel, Anke, Khouja, Mouhamad, Stewart, Peter, Strifler, Susanne, Stuebig, Thomas, Kull, Miriam, Baldus, Claudia, Pott, Christiane, Gonzalez de Castro, David, Engelhardt, Monika, Krönke, Jan, Einsele, Hermann, Knop, Stefan, Brüggemann, Monika

Get full text

Towards a One Health Food Safety Strategy for Palestine: A Mixed-Method Study by Abukhattab, Said, Kull, Miriam, Abu-Rmeileh, Niveen M E, Cissé, Guéladio, Crump, Lisa, Hattendorf, Jan, Zinsstag, Jakob

“…Foodborne diseases, together with increasing antimicrobial resistance (AMR), pose a threat to public health in an era of huge challenges with climate change…”
Get full text

Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532 by El-Daly, Hesham, Kull, Miriam, Zimmermann, Stefan, Pantic, Milena, Waller, Cornelius F., Martens, Uwe M.

“…Telomerase represents an attractive target for a mechanism-based therapeutic approach because its activation has been associated with unlimited proliferation…”
Get full text

S189: PROTEOGENOMIC LANDSCAPE OF MULTIPLE MYELOMA by Ramberger, Evelyn, Dolnik, Anna, Ng, Yuen Lam Dora, Ziehm, Matthias, Popp, Oliver, Sträng, Eric, Kull, Miriam, Sapozhnikova, Valeriia, Grünschläger, Florian, Benary, Manuela, Müller, Sina, Gao, Xiang, Murgai, Arunima, Haji, Mohamed, Schmidt, Annika, Lutz, Raphael, Nogai, Axel, Braune, Jan, Laue, Dominik, Langer, Christian, Khandanpour, Cyrus, Bassermann, Florain, Döhner, Hartmut, Engelhardt, Monika, Straka, Christian, Hundemer, Michael, Haas, Simon, Beule, Dieter, Keller, Ulrich, Einsele, Hermann, Bullinger, Lars, Knop, Stefan, Mertins, Philipp, Krönke, Jan

Get full text

Immunophenotypical profiling of myeloid neoplasms with erythroid predominance using mass cytometry (CyTOF) by Maag, Abdul‐Habib, Swanton, Helen, Kull, Miriam, Vegi, Naidu M., Feuring, Michaela

“…Acute erythroid leukemia (AEL) is a disease continuum between Myelodysplastic syndrome (MDS) and Acute myeloid leukemia (AML) with the cellular hallmark of…”
Get full text

Cereblon enhancer methylation and IMiD resistance in multiple myeloma by Haertle, Larissa, Barrio, Santiago, Munawar, Umair, Han, Seungbin, Zhou, Xiang, Vogt, Cornelia, Fernández, Rafael Alonso, Bittrich, Max, Ruiz-Heredia, Yanira, Da Viá, Matteo, Zovko, Josip, Garitano-Trojaola, Andoni, Bolli, Niccolò, Ruckdeschel, Anna, Stühmer, Thorsten, Chatterjee, Manik, Kull, Miriam, Krönke, Jan, Agirre, Xabier, Martin-Subero, Jose I., Raab, Peter, Einsele, Hermann, Rasche, Leo, Martinez-Lopez, Joaquin, Haaf, Thomas, Kortüm, K. Martin

“…Cereblon is the direct binding target of the immunomodulatory drugs (IMiDs) that are commonly used to treat multiple myeloma (MM), the second most frequent…”
Get full text

Real-World Analysis of Teclistamab in 115 RRMM Patients from Germany by Riedhammer, Christine, Bassermann, Florian, Besemer, Britta, Bewarder, Moritz, Brunner, Franziska, Carpinteiro, Alexander, Einsele, Hermann, Faltin, Josefine, Frenking, Jan, Gezer, Deniz, Goldman-Mazur, Sarah, Hanel, Mathias, Hoegner, Marion, Kortüm, K. Martin, Krönke, Jan, Kull, Miriam, Leitner, Theo, Mann, Christoph, Mecklenbrauck, Rabea, Merz, Maximilian, Morgner, Anke, Nogai, Axel, Raab, Marc S., Teipel, Raphael, Wäsch, Ralph, Rasche, Leo

“…Background Bispecific antibodies and CAR-T cells are currently changing the treatment landscape of relapsed and refractory multiple myeloma (RRMM), having…”
Get full text

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study by Knop, Stefan, Stuebig, Thomas, Kull, Miriam, Greil, Richard, Steiner, Normann, Bassermann, Florian, Nogai, Axel, von Lilienfeld-Toal, Marie, Janjetovic, Snjezana, Trautmann-Grill, Karolin, Bittrich, Max, Engelhardt, Monika Martha, Hoferer, Anette, Theurich, Sebastian, Binder, Mascha, Zojer, Niklas, Duerk, Heinz A., Brueggemann, Monika, Held, Swantje, Einsele, Hermann

“…8000 Background: In medically fit patients with newly diagnosed (ND) multiple myeloma (MM), triplet or quadruplet induction regimens, high-dose chemotherapy…”
Get full text

Impact of ABCB1 Promoter Methylation on PI-Resistance in Multiple Myeloma by Han, Seungbin, Haertle, Larissa, Besse, Lenka, Lee, Chien-Yun, Zhou, Xiang, Munawar, Umair, Besse, Andrej, Kull, Miriam, Bittrich, Max, Steinhardt, Max Johannes, Mersi, Julia, Teufel, Eva, Nerreter, Silvia, Vogt, Cornelia, Danhof, Sophia, Krönke, Jan, Weinhold, Niels, Raab, Marc S, Haaf, Thomas, Driessen, Christoph, Einsele, Hermann, Rasche, Leo, Küster, Bernhard, Kortuem, Martin

Get full text

Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma by Straka, Christian, Schaefer-Eckart, Kerstin, Hertenstein, Bernd, Bassermann, Florian, Salwender, Hans, Langer, Christian, Krönke, Jan, Kull, Miriam, Schilling, Georgia, Schieferdecker, Aneta, Engelhardt, Monika, Knop, Stefan, Reusch, Julia, Roesler, Wolf, Metzner, Bernd, Hebart, Holger, Reichle, Albrecht, Grube, Matthias, Frickhofen, Norbert, Gerecke, Christian, Fuhrmann, Stephan, Jung, Wolfram, Gramatzki, Martin, Decker, Thomas, Dechow, Tobias, Greiner, Jochen, Brümmendorf, Tim H., Ababei, Juliana, Metzler, Ivana von, Naumann, Ralph, Fritz, Elisabeth, Hentrich, Marcus, Bojko, Peter, Kubin, Thomas, Schmidt, Christian, Kaufmann, Martin, Schmidt, Burkhard, Hinke, Axel, Einsele, Hermann

Get full text

The Integrated Glasgow Prognostic- and Cytogenetic Risk Score (CytoGPS) at Diagnosis Is a Strong and Independent Predictor of Survival in Transplant-Eligible Patients with Multiple Myelom by Witte, Hanno Maximilian, Biersack, Harald, Riecke, Armin, Bonorden, Bastian, Kopelke, Svenja, Merz, Hartmut, Bernard, Veronica, Lehnert, Hendrik, Kull, Miriam, Fetscher, Sebastian, Gebauer, Niklas

“…Abstract Introduction: Immunity and inflammatory response impact tumor microenvironment and progression of malignancies. Metabolic and inflammatory parameters…”
Get full text

Exome Sequencing of Relapsed Multiple Myeloma Combined with Pooled CRISPR/Cas9 Screens Identifies Gene Mutations Associated with Drug-Specific Resistance by Bohl, Stephan, Schmalbrock, Laura K., Bauhuf, Imke, Dolnik, Anna, Blätte, Tamara J., Lindner, Stefanie, Meyer, Tatjana, Knödler, Sarah, Miller, Denise, Kull, Miriam, Langer, Christian, Döhner, Hartmut, Heckl, Dirk, Bullinger, Lars, Krönke, Jan

“…Lenalidomide, bortezomib, melphalan and dexamethasone are standard drugs for the treatment of multiple myeloma (MM). Although many patients initially respond…”
Get full text

P-021 A German Multicenter Real-World Analysis of Talquetamab in 102 Patients With Relapsed/Refractory Multiple Myeloma by Frenking, Jan, Riedhammer, Christine, Besemer, Britta, Braune, Jan, Brioli, Annamaria, Brunner, Franziska, Dampmann, Maria, Gezer, Deniz, Goldman-Mazur, Sarah, Hänel, Mathias, Hanoun, Christine, Högner, Marion, Kolditz, Katja, Kos, Igor, Kull, Miriam, Leitner, Theo, Merz, Maximilan, Metzler, Ivana von, Michel, Christian S., Teipel, Raphael, Theurich, Sebastian, Wäsch, Ralph, Zukovs, Romans, Rasche, Leo, Raab, Marc-Steffen

Get full text

First clinical experience of isatuximab safety and tolerability in relapsed and refractory multiple myeloma: real-world data from a compassionate use program in Germany by Theo Leitner, Cyrus Khandanpour, Cyrus Khandanpour, Knut Wendelin, Fuat Oduncu, Christoph Kimmich, Ralph Naumann, Miriam Kull, Hartmut Goldschmidt, Martin Ehmer, Claudia Kiewitz, Hans Salwender

“…Therapy for relapsed and refractory multiple myeloma (RRMM) remains challenging. While monoclonal antibodies against CD38 combined with pomalidomide have…”
Get full text

Targeted sequencing using a 47 gene multiple myeloma mutation panel (M3P) in ‐17p high risk disease by Kortüm, Klaus M., Langer, Christian, Monge, Jorge, Bruins, Laura, Egan, Jan B., Zhu, Yuan X., Shi, Chang Xin, Jedlowski, Patrick, Schmidt, Jessica, Ojha, Juhi, Bullinger, Lars, Liebisch, Peter, Kull, Miriam, Champion, Mia D., Van Wier, Scott, Ahmann, Gregory, Rasche, Leo, Knop, Stefan, Fonseca, Rafael, Einsele, Hermann, Stewart, A Keith, Braggio, Esteban

“…Summary We constructed a multiple myeloma (MM)‐specific gene panel for targeted sequencing and investigated 72 untreated high‐risk (del17p) MM patients…”
Get full text